Cerebras Shares Slide as Margin Guidance Overshadows Q1 Earnings Beat
The AI chipmaker's stock fell toward its IPO price after the company projected a sharp decline in gross margins for the second quarter.
Cerebras Systems shares dropped toward their initial public offering price this week after the company issued cautious margin guidance in its first quarterly report as a public entity. The selloff occurred despite the chipmaker exceeding analyst expectations for both revenue and losses.
Shares of the AI hardware firm fell to approximately $188.56, placing the stock near its $185 IPO price. The decline follows a report showing Q1 2026 revenue of $193.4 million, which topped Wall Street consensus estimates. However, investors focused on the company's outlook for the current quarter, where gross margin guidance was set between 36% and 38%—a significant drop from the approximately 46.5% to 47% posted in the first quarter.
The AI Hardware Race
Cerebras Systems operates in the highly competitive data center accelerator market, positioning itself as a primary challenger to Nvidia. The company recently entered the public market through a massive IPO that raised $6.4 billion. While the stock experienced a substantial surge immediately following its debut, the current volatility reflects a shift in how the market evaluates the company's growth trajectory relative to its costs.
Margin Sustainability Concerns
This reaction underscores the market's extreme sensitivity to unit economics and margin sustainability for AI hardware providers. While strong revenue growth is a positive indicator, the projected compression in gross margins raises questions about whether Cerebras can maintain the high profitability levels typically associated with premium semiconductor firms. For investors, the ability to scale revenue without sacrificing margins is the primary benchmark for justifying the high valuations currently seen in the AI sector.
Divergent Outlooks
Despite the immediate market reaction, some analysts suggest the company may be guiding conservatively. Morgan Stanley raised its price target for CBRS to $273 from $250, signaling confidence in the company's long-term value despite the short-term margin dip. Market observers will now watch for Q2 results to see if the margin compression is a temporary adjustment or a structural trend in the company's pricing and production model.